CHOP Study Finds Safest Treatment for Immunodeficiency Disorder is Not Cost Effective for U.S. Patients
Published on
Using a model developed at CHOP, researchers find high cost of treatment most likely to prevent premature death in patients with agammaglobulinemia undermines its benefits.